Osteoarthritis trial results propel Paradigm shares 19pc
Yolanda RedrupRich List co-editor
Shares in listed drug repurposing business Paradigm Biopharmaceuticals surged 19 per cent on Tuesday afternoon, buoyed by positive clinical trial results for its osteoarthritis drug candidate.
The company, founded in 2014 by former CEO Paul Rennie, is hoping to commercialise a new treatment for osteoarthritis by repurposing existing drug pentosan polysulphate sodium (PPS), which historically had been used as a mild blood thinner.
Subscribe to gift this article
Gift 5 articles to anyone you choose each month when you subscribe.
Subscribe nowAlready a subscriber?
Introducing your Newsfeed
Follow the topics, people and companies that matter to you.
Find out moreRead More
Latest In Healthcare & fitness
Fetching latest articles